

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 862 648 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
**06.10.2004 Bulletin 2004/41**

(51) Int Cl.7: **C12Q 1/00**, A61B 5/145,  
G01N 33/66

(21) Application number: **96941438.2**

(86) International application number:  
**PCT/US1996/018720**

(22) Date of filing: **21.11.1996**

(87) International publication number:  
**WO 1997/019188 (29.05.1997 Gazette 1997/23)**

### (54) DETECTION OF BIOLOGICAL MOLECULES USING CHEMICAL AMPLIFICATION AND OPTICAL SENSORS

DETEKTION VON BIOLOGISCHEN MOLEKÜLEN UNTER VERWENDUNG VON CHEMISCHER  
AMPLIFIKATION UND OPTISCHEM SENSOR

DETECTION DE MOLECULES BIOLOGIQUES PAR AMPLIFICATION CHIMIQUE ET AU MOYEN  
DE DETECTEURS OPTIQUES

(84) Designated Contracting States:  
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE**

(30) Priority: **22.11.1995 US 7515 P**

(43) Date of publication of application:  
**09.09.1998 Bulletin 1998/37**

(73) Proprietor: **Medtronic MiniMed, Inc.**  
**Northridge, CA 91325-1219 (US)**

(72) Inventors:  
• **VAN ANTWERP, William, Peter**  
**Valencia, CA 91355 (US)**  
• **MASTROTOTARO, John, Joseph**  
**Los Angeles, CA 90025 (US)**

(74) Representative: **Goldin, Douglas Michael et al**  
**J.A. KEMP & CO.**  
**14 South Square**  
**Gray's Inn**  
**London WC1R 5JJ (GB)**

(56) References cited:  
**US-A- 4 680 268** **US-A- 5 342 789**

- **DIABETES, Volume 44, September 1966, David A. Gough et al, "Perspectives in Diabetes. Development of the Implantable Glucose Sensor. What Are the Prospects and Why Is It Taking So Long?"**
- **NAKASHIMA ET AL: 'Sugar-assisted chirality control of Tris(2,2'-bipyridine)-metal complexes' CHEMISTRY LETTERS 1994, pages 1267 - 1270**
- **JAMES ET AL: 'Novel photoinduced electron-transfer sensor for saccharides based on the interaction of boronic acid and amine' J. CHEM. SOC., CHEM. COMMUN. 1994, pages 477 - 478**
- **JAMES ET AL: 'Chiral discrimination of monosaccharides using a fluorescent molecular sensor' NATURE vol. 374, 1995, pages 345 - 347**
- **YOON ET AL: 'Fluorescent chemosensors of carbohydrates. A means of chemically communicating the binding of polypols in waer based on chelation-enhanced quenching' J, AM. CHEM. SOC. vol. 114, 1992, pages 5874 - 5875**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 0 862 648 B1**

**Description****FTELD OF THE INVENTION**

5 [0001] This invention relates generally to biological sensors. More specifically, this invention relates to minimally invasive amplification systems and optical sensors capable of detecting polyhydroxylated compounds such as glucose.

**BACKGROUND OF THE INVENTION**

10 [0002] An essential tool for the care of the diabetic patient is the measurement of blood glucose. Recently, the NIDDK (National Institutes of Diabetes and Digestion and Kidney Diseases) has released the results of a large clinical trial, the DCCT (Diabetes Control and Complications Trial) that shows conclusively that improved blood glucose control reduces the risk of long term complications of diabetes. See, DCCT Research Group, *N. Engl. J. Med.* 329:977-986 (1993).

15 [0003] Current technology requires that a blood sample be obtained for measurement of blood glucose levels. Samples of venous blood can be obtained from the patient for this measurement, but this method is limited to only a few samples per day, and is not practical for the care of outpatients.

[0004] Self monitoring of capillary blood glucose is practical, but still requires multiple and frequent skin punctures. Consequently, most patients perform 2-6 tests per day depending on their personal circumstances and medical condition. Self monitoring results are influenced by technique errors, variability of sample volume and impaired motor skills (important with hypoglycemic episodes). The patient must interrupt other activities to perform the task of blood glucose measurement.

[0005] The concept of an implantable sensor to continuously measure the glucose levels in holter monitor type applications and in ambulatory diabetic individuals has existed for several decades. For a recent discussion, see Reach, *et al.*, *Anal. Chem.* 64:381-386 (1992). The primary focus has been to overcome the disadvantages of capillary blood glucose self-monitoring by developing a glucose sensor, which at the very least, would provide more frequent and easily acquired glucose information. In addition, the sensor could function as a hypoglycemic and hyperglycemic alarm, and ultimately serve as the controller for an artificial endocrine pancreas. The potential limitations of this approach include the limited life of the enzyme, glucose oxidase, the limited lifetime of the sensor (2-3 days), and the need to wear the device.

[0006] The concept of a non-invasive glucose sensor has received significant media and technical attention over the past several years. The basic scientific goal has been to utilize near infrared (NIR) spectrophotometry to detect the absorbance properties of the glucose molecule. The inherent problem with this approach is that the glucose signal is weak and is masked by other body constituents. Moreover, if it is possible to detect glucose, the system will most likely rely upon expensive optics and significant computing power, resulting in a large, expensive device which requires frequent recalibration to the patient and provides intermittent data.

[0007] Some of the approaches to non-invasive blood glucose measurement are described in U.S. Patent Nos. 4,428,366, 4,655,225, 4,805,623, 4,875,486, 4,882,492, 5,028,787, 5,054,487, 5,070,874, 5,077,476, 5,086,229, and 5,112,124.

40 [0008] Most of these approaches involve the use of transdermal infrared or near infrared radiation in either a transmission or reflectant mode. In spite of the large number of patents and intense efforts by at least thirty major companies, no devices have been successfully implemented in the field.

[0009] The problems with these approaches are well known and described in detail by Marquardt, *et al.*, *Anal. Chem.*, 65:3271 (1993) and Arnold, *et al.*, *Anal. Chem.*, 62:1457 (1990). Marquardt, *et al.* have shown that in a simple aqueous solution, the absorbance of a 13mM glucose solution (234 mg/dl) gave a signal with a S/N ratio of about 2. In a protein containing matrix, the actual signal from glucose cannot be detected without considerable manipulation of the data using a partial least squares approach. Such small signal to noise ratios are not practical for developing robust simple instrumentation. Furthermore, the device used in this research is a large spectrophotometer that must be able to scan over reasonably broad wavelength ranges.

50 [0010] In contrast to these purely non-invasive optical approaches, an implant containing a transducer chemical whose optical properties are strongly modulated by recognition of the target analyte will result in a large amplification of the optical signal. It is in this sense that the term "chemical amplification" is used throughout this application. For instance, U.S. Patent 4,401,122 describes an implanted enzymatic sensor that measures the  $H_2O_2$  produced when glucose and oxygen react in the presence of the enzyme glucose oxidase. This approach is limited by profound biocompatibility concerns, particularly changes in stability related to glucose diffusion to the sensor and the lifetime of an enzyme in an implanted environment. Further concerns using enzymes are created because the large differential between  $O_2$  and glucose concentrations in the body requires a glucose limiting outer membrane. This membrane limits not only the glucose, but the analytical signal as well.

[0011] U.S. Patent No. 4,680,268 discloses an implantable biosensor for sensing products, such as hydrogen peroxide, generated from an enzymatic reaction between an analyte, like glucose, and an enzyme in the presence of oxygen.

[0012] One approach to solving the problems is described in U.S. Patent 5,342,789. In this approach, a fluorescent labelled glycoprotein competes with glucose for binding to a differently fluorescent labeled lectin. Because there is some resonance energy transfer from one label to the other, the presence of glucose reduces the fluorescence intensity of the system. There are two major drawbacks to the system as described in the '789 patent. The first problem is that both labels are photoexcited by the same source; the background signal is significant. The second problem is related to the ability of the system to be implanted into the body. The resonance energy transfer requires diffusion of glucose to the lectin and diffusion of the labeled glycoprotein away from the lectin. In order for the system to have a reasonable time constant for physiological applications, the reagents must be in solution and free to diffuse via a concentration gradient. This makes the device difficult to implement reliably since a reservoir must be designed which allows glucose to diffuse in but prevents the proteins and lectin from diffusing out.

[0013] Accordingly, there has been a need for a glucose sensor able to measure glucose over the entire physiological range of 30 to 500+ mg/dl (1.6 to 28+mM). It should provide continuous glucose information and be easy to use. The sensor would not require a sample of blood and would be pain free. From an analytical chemistry standpoint, both the accuracy and the precision would be greater than 95% and the sensor should be non-invasive or minimally invasive. From an instrumental point of view, the device should have a linear dynamic range of at least 200 and a signal to noise ratio of at least 50. Attainment of these figures will ensure that analytical precision and accuracy can be achieved. However, less sensitive instruments could be useful providing measurement of the analyte signals is accurate. The present invention fulfills these needs and provides other related advantages.

## SUMMARY OF THE INVENTION

[0014] The present invention provides methods for the determination of biological levels of polyhydroxylated compounds, particularly glucose. The methods utilize an amplification system which is implantable and which produces a signal capable of detection, typically external to the skin of a mammal, for example, a human. The amplification system is an analyte transducer which is immobilized in a polymeric matrix. Generation of a signal by the amplification system is typically the result of interrogation by an optical source. Importantly, the signal does not require resonance energy transfer, but instead relies on electron transfer (e.g., molecular electron transfer or photoelectron transfer). Detection of the signal produced then determines the quantity of polyhydroxylated compound or analyte of interest.

[0015] There are therefore two important aspects of the invention. The first is an implantable amplification system (IAS) comprising a biocompatible polymer matrix and amplification components which produce a polyhydroxylated analyte signal upon interrogation by an optical system, wherein said amplification components comprise an arylboronic acid moiety attached to an amine-functionalized dye molecule, and wherein said amplification components do not require resonance energy transfer for production of said signal. The second aspect of the invention is a biosensor for measuring the amount of polyhydroxylated analyte *in vivo*, said sensor comprising:

(a) an implantable system of the invention; and

(b) an optical system comprising an optical source and a detector which detects said signal thereby measuring the *in vivo* amount of said analyte.

[0016] The optical system interrogates the immobilized amplification components to produce a detectable signal. In some embodiments, the optical system is a transdermal optical system, while in other embodiments a fiber optic system is used.

## BRIEF DESCRIPTION OF THE DRAWINGS

[0017]

FIGURE 1 shows a schematic of the optical glucose monitoring system.

FIGURE 2 illustrates a schematic of an optical analyte monitoring system which further illustrates the binding of a polyhydroxylated analyte to an amplification component following permeation into a biocompatible matrix.

FIGURE 3 illustrates one embodiment of the invention which uses a fiber optic bundle as a "light pipe" for interrogation of an implanted amplification system.

FIGURE 4 illustrates another embodiment of the invention which uses a subcutaneous light source for interrogation of an implanted amplification system.

FIGURE 5 illustrates another embodiment of the invention which uses a subcutaneous light source and detector

to provide a completely subdermal analyte monitoring system.

FIGURE 6 illustrates another embodiment of the invention which uses a subcutaneous light source and detector to provide a completely subdermal analyte monitoring system which is coupled to an analyte source or medicament pump (*e.g.*, an insulin pump) to provide a "closed loop" monitoring and supplementation system (*e.g.* an artificial pancreas).

FIGURE 7 shows the reversible interaction between a polyhydroxylated analyte such as glucose and a boronate complex, N-methyl-N-(9-methylene anthryl)-2-methylenephénylboronic acid.

FIGURE 8 provides the structures for a number of boronate compounds of formula I, along with excitation and emission wavelengths.

FIGURE 9 illustrates a synthesis scheme for boronate complexes which are useful as amplification components. FIGURE 10 illustrates another synthesis scheme for boronate complexes which are useful as amplification components.

FIGURE 11 provides three examples of implantable amplification systems for the immobilization of amplification components.

FIGURE 12 provides a calibration curve for the quenching of fluorescence intensity by glucose at pH 7.4.

FIGURE 13 shows reversible fluorescence versus glucose concentration for an anthracene boronate solution.

## DETAILED DESCRIPTION OF THE INVENTION

**[0018]** The following abbreviations are used herein: dl, deciliter; DEG, diethylene glycol; DMF, dimethylformamide; IAS, implantable amplification system; PBS, phosphate buffered saline; THF, tetrahydrofuran; DI, deionized; PEG, poly(ethylene)glycol; mv, millivolts; mg, milligrams.

### General —

**[0019]** The broad concept of the present invention is illustrated in FIGURE 1. As can be seen, the basic scheme utilizes both a detector and source module which can be external to the skin. The source provides an excitation signal which interrogates a subcutaneous amplification system. The system then produces an amplified signal which is monitored by the external detector.

**[0020]** The amplification system can be implanted into a variety of tissues. Preferably, the system is implanted subcutaneously at a depth of from 1 to 2 mm below the surface of the skin. At this depth the system is most easily implanted between the dermis layer and the subcutaneous fat layer. These layers, in mammals are relatively easily separated and an amplification system (*e.g.*, chemical amplification components in a biocompatible polymer) can be inserted into a small pocket created in a minor surgical procedure. The implanted system can be perfused by capillary blood and made of a material through which glucose can easily diffuse. Alternatively, the amplification system can be placed in contact with other fluids containing the analyte of interest.

**[0021]** In one group of embodiments (illustrated in FIGURE 1), the amplification system contains an immobilized chemical amplification component which may contain a fluorescent moiety providing a signal which is modulated by the local analyte concentration. A filter can also be incorporated into the system for the fluorescent photons (for those embodiments in which a fluorescent dye is used). The implanted amplification system is interrogated transdermally by a small instrument worn or placed over the implant. The small instrument contains a light source (*e.g.*, a filtered LED) and a filtered detector (*e.g.*, a photomultiplier tube, an unbiased silicon photodiode). The signal from the detector provides a continuous reading of the patient's analyte level which can also be used as input to, for example, an insulin pump or a visual reading for the patient. Alternative embodiments are described below (*e.g.*, use of a fiber optic for interrogation of the amplification system).

**[0022]** FIGURE 2 provides yet another schematic which illustrates the amplification system. According to this figure, the amplification system includes a permeable membrane, a matrix for immobilizing the amplification components, and the amplification components themselves. The polyhydroxylated analyte can then permeate the matrix, bind to the amplification components and produce a signal upon interrogation which is collected, filtered and detected. The optical sources can be a variety of light sources (*e.g.* laser diode, LED) and the light can be delivered to the amplification system via delivery methods which could include lenses and fiber optics. Alternatively, the optical interrogation can take place with transdermal illumination. The resultant signal can be collected, again via a fiber optic or lens, and sent to the detector, with the optional use of an intervening filter or discriminator.

**[0023]** In addition to the embodiments generally described in FIGURES 1-2, the present invention provides sensing systems and methods as generally illustrated in FIGURES 3-6.

**[0024]** In FIGURE 3, a light source is positioned external to the skin and the amplification system is placed at or coated on the distal end of a fiber optic, which is inserted through the skin into a subcutaneous layer. The fiber optic serves to conduct the light from the source to the amplification system, and then collects the light emitted from the

amplification system and conducts it back to the detector.

[0025] Yet another embodiment is provided in FIGURE 4. According to this figure, the light source is also implanted under the dermis. Upon interrogation of the IAS by the internal light source, the IAS provides a signal which is transdermally transmitted to an external detector.

[0026] In still another embodiment (FIGURE 5), the light source and detector are both implanted under the dermis. The detector then provides transmission of the information to an output reading device which is external to the skin.

[0027] Finally, for those embodiments in which glucose levels are determined, some aspects of the invention are directed to coupling of the detector signal to an insulin pump system in a "closed-loop" artificial pancreas (see FIGURE 6).

[0028] As a result of the above descriptions, the biosensors of the present invention comprise two important components. The first component is an implantable amplification system or IAS, which includes both signal amplification components and a polymer matrix. Additionally, an important feature of the present invention is the immobilization of the amplification components in the polymer matrix. The immobilization can be carried out by physical entrapment or by covalent attachment. The second component is the optical system which utilizes transdermal or fiber optic transmission of light or signal.

### Implantable Amplification Systems (IAS)

[0029] In one aspect, the present invention provides an implantable amplification system which is a combination of an analyte signal transducer or amplification components and a polymer matrix, preferably a biocompatible matrix.

### Equilibrium Binding Methods

[0030] Non-enzymatic equilibrium-based amplification methods for polyhydroxylated analyte (*e.g.*, glucose) amplification are preferable to enzymatic ones, because the ability of an enzyme to maintain its activity over long periods of time in the body is limited. In addition, enzymatic approaches based on O<sub>2</sub> consumption (for glucose measurement) suffer from the inherent deficiency of O<sub>2</sub> vs. glucose in the body and require a differentially permeable outer membrane.

[0031] The equilibrium binding approach employed in the invention uses boronate based sugar binding compounds. The basic interaction between a sugar such as glucose and a labelled boronate complex is shown in FIGURE 7. The binding of glucose to the boronate group is reversible as shown in FIGURE 7. In one case, the fluorescence of the boronate compounds is changed upon addition of glucose. In other cases, fluorescence enhancement or quenching occurs due to intramolecular electron transfer. See, Falasca, *et al.*, *Biochim. Biophys. Acta.*, **577**:71 (1979); Nakashima and Shinkai, *Chemistry Letters*, 1267 (1994); and James, *et al.*, *J. Chem. Soc. Chem. Commun.*, 277 (1994). In some boronate complexes, modification of the acidity of the Lewis acid boron center is changed upon glucose binding.


[0032] Boronate complexes have been described which transduce a glucose signal through a variety of means. See, Nakashima, *et al.*, *Chem. Lett.* 1267 (1994); James, *et al.*, *J. Chem. Soc. Chem. Commun.*, 477 (1994); and James *et al.*, *Nature*, 374:345 (1995). These include geometrical changes in porphyrin or indole type molecules, changes in optical rotation power in porphyrins, and photoinduced electron transfer in anthracene type moieties. Similarly, the fluorescence of 1-anthrylboronic acid has been shown to be quenched by the addition of glucose. See Yoon, *et al.*, *J. Am. Chem. Soc.*, **114**:5874 (1992). A postulated mechanism for this effect is that of a shift in the Lewis acidity of the boronate group upon complexation of a diol. All these published approaches describe signal transduction systems only.

[0033] An application to actual *in vivo* sensing for the above approaches must also encompass the immobilization of the transduction system into a suitable polymer system, which is preferably a biocompatible polymer. In the present invention, the transduction system, or signal amplification components are entrapped within a suitable polymer matrix. Alternatively, the amplification components can be covalently attached to, and surrounded by the polymer matrix. Covalent attachment of the components to a polymer matrix prevents leakage of the components to surrounding tissue, and other undesirable contact of the amplification components with non-target fluids.

[0034] In the invention, the amplification components comprise an arylboronic acid moiety attached to an amine-functionalized dye molecule. The linkage between the arylboronic acid moiety and the dye molecule will typically be from about two to about four carbon atoms, interrupted by nitrogen. Certain non-limiting examples of suitable linkages include —CH<sub>2</sub>-NH-CH<sub>2</sub>—, —(CH<sub>2</sub>)<sub>2</sub>-NH-CH<sub>2</sub>—, —C(O)CH<sub>2</sub>-NH-CH<sub>2</sub>—, —CH<sub>2</sub>-NR-CH<sub>2</sub>—, —(CH<sub>2</sub>)<sub>2</sub>-NR-CH<sub>2</sub>—, and —C(O)CH<sub>2</sub>-NR-CH<sub>2</sub>—, in which the R group is an alkyl substituent of from 1 to about 8 carbon atoms. As used herein the term "alkyl" refers to a saturated hydrocarbon radical which may be straight-chain or branched-chain (for example, ethyl, isopropyl, *t*-amyl, or 2,5-dimethylhexyl). This definition applies both when the term is used alone and when it is used as part of a compound term, such as "haloalkyl" and similar terms. Preferred alkyl groups are those containing 1 to 6 carbon atoms. All numerical ranges in this specification and claims are intended to be inclusive of their upper and lower limits. Additionally, the alkyl group which is attached to a nitrogen atom in the linkages above will preferably be substituted with a functional group such as hydroxy, amino or thiol which will facilitate the covalent

attachment of the amplification component to a biocompatible matrix.

[0035] In a related group of embodiments, the implantable amplification system incorporates a compound of the formula:



In this formula, D<sup>1</sup> represents a dye which can be a fluorescent dye, a luminescent dye or colorimetric dye. The symbols R<sup>1</sup>, R<sup>3</sup> and R<sup>4</sup> each independently represent substituents which alter the electronic properties of the groups to which they are attached or which contain functional groups capable of forming covalent linkages to the surrounding polymer matrix. Preferably, R<sup>1</sup>, R<sup>3</sup> and R<sup>4</sup> are each independently hydrogen, hydroxy, acyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen, thiol, sulfonic acid, sulfonamide, sulfamic acid, nitro, cyano, carboxylic acid, a C<sub>1</sub>-C<sub>12</sub> alkyl group, a substituted C<sub>1</sub>-C<sub>12</sub> alkyl group, a C<sub>1</sub>-C<sub>12</sub> alkenyl group, a substituted C<sub>1</sub>-C<sub>12</sub> alkenyl group, a C<sub>1</sub>-C<sub>12</sub> alkynyl group, a substituted C<sub>1</sub>-C<sub>12</sub> alkynyl group, aryl, substituted aryl, arylalkyl, substituted arylalkyl, amine, or substituted amine. For each of the substituted species above, the substituents are preferably hydroxy, acyl, aryl, C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen, thiol, sulfonic acid, amines, sulfonamide, sulfamic acid, nitro, cyano, carboxamide or carboxylic acid. In particularly preferred embodiments, R<sup>1</sup>, R<sup>3</sup> and R<sup>4</sup> are each independently hydrogen, hydroxy, C<sub>1</sub>-C<sub>4</sub> acyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, halogen, thiol, sulfonic acid, sulfonamide, nitro, cyano, carboxylic acid, a C<sub>1</sub>-C<sub>4</sub> alkyl group, a C<sub>1</sub>-C<sub>4</sub> alkenyl group, a C<sub>1</sub>-C<sub>4</sub> alkynyl group, aryl, arylalkyl, or amine.

[0036] Each of the R<sup>2</sup> symbols independently represents hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl, or taken together the two R<sup>2</sup> groups form a C<sub>2</sub>-C<sub>5</sub> alkylene chain. Preferably, the R<sup>2</sup> groups are both hydrogen.

[0037] Each of L<sup>1</sup> and L<sup>2</sup> independently represent a linking group having from zero to four contiguous atoms, preferably one to two. The linking groups are preferably alkylene chains (*e.g.*, methylene, ethylene, propylene, or butylene). Alternatively, the alkylene chains can have one or more of the carbon atoms replaced by a oxygen, nitrogen, sulfur or phosphorus, with the understanding that any remaining valences on the heteroatoms can be occupied by hydrogen, hydroxy groups or oxo groups. Preferably, the heteroatoms when present, are oxygen or nitrogen.

[0038] The symbol Z represents a nitrogen, sulfur, oxygen or phosphorus. One of skill would understand that for those embodiments in which Z is oxygen, R<sup>1</sup> will not be present. Additionally, as above, any remaining valences on the heteroatoms can be occupied by hydrogen, hydroxy groups or oxo groups. Preferably, Z is nitrogen. The symbol x is an integer of from zero to four.

[0039] The chemical terms used herein are taken to have their accepted meanings to one of skill in the chemical arts. For example, the term "alkoxy" refers to an alkyl radical as described above which also bears an oxygen substituent which is capable of covalent attachment to another hydrocarbon radical (such as, for example, methoxy, ethoxy, and *t*-butoxy). "Halogen" is meant to include —F, —Cl, —Br and —I, although —F and —Cl are preferred. The term "alkenyl" as used herein refers to an alkyl group as described above which contains one or more sites of unsaturation. The term "alkynyl" as used herein refers to an alkyl group as described above which contains one or more carbon-carbon triple bonds. The term "aryl" refers to an aromatic substituent which may be a single ring or multiple rings which are fused together, linked covalently or linked to a common group such as an ethylene or methylene moiety. The aromatic rings may each contain heteroatoms, for example, phenyl, naphthyl, biphenyl, diphenylmethyl, 2,2-diphenyl-1-ethyl, thienyl, pyridyl and quinoxalyl. The aryl moieties may also be optionally substituted as discussed above. Additionally, the aryl radicals may be attached to other moieties at any position on the aryl radical which would otherwise be occupied by a hydrogen atom (such as, for example, 2-pyridyl, 3-pyridyl and 4-pyridyl). The term "arylalkyl" refers to an aryl radical attached directly to an alkyl group.

[0040] Preferably, the dye used in formula (I) is an anthracene, fluorescein, xanthene (*e.g.*, sulforhodamine, rhodamine), cyanine, coumarin (*e.g.*, coumarin 153), oxazine (*e.g.*, Nile blue), a metal complex or other polyaromatic hydrocarbon which produces a fluorescent signal. Structures for some of the embodiments of formula I are provided in FIGURE 8 along with the excitation and emission wavelengths for each. Particularly preferred are long wavelength fluorescent dyes having emission wavelengths of at least about 450 nm, preferably from 450 to about 800 nm. Shorter wavelength dyes typically do not provide sufficient signal through the skin. As a result, shorter wavelength dyes are suitable for applications in which interrogation and signal delivery is by means of a fiber optic. Preferred shorter wavelength dyes are those having emission wavelengths of about 320 nm to about 450 nm.

[0041] The compounds used in this aspect of the invention can be prepared by the methods described in the examples below or by modifications thereof. FIGURE 9 provides one synthesis scheme for the compounds of formula I. In this scheme, 9-anthraldehyde (available from commercial sources such as Aldrich Chemical Co., Milwaukee, Wisconsin,

USA) can be treated with 5-amino-1-pentanol (Aldrich) under reductive amination conditions using sodium borohydride in methanol. The resulting secondary amine can then be alkylated with a bromomethyl arylboronic acid derivative to provide a protected amplification component.

[0042] FIGURE 10 provides another synthesis scheme for the compounds of formula I. In this scheme, 10-(hydroxymethyl)-9-anthraldehyde (prepared according to the methods described in Lin, *et al.*, *J. Org. Chem.* **44**:4701 (1979)) is reductively aminated using methylamine in a two-step process involving imine formation followed by sodium borohydride reduction of the imine. Alkylation of the secondary amine with a suitable arylboronic acid derivative then provides the desired compound of formula I. In this family of compounds, the D<sup>1</sup> moiety (*e.g.*, anthracene) has an attached hydroxymethyl group which facilitates covalent attachment of the compound to a biocompatible matrix.

#### Spectroscopic Method

[0043] One approach to minimally invasive glucose sensing is by surface enhanced resonance Raman spectroscopy. The glucose is bound to a boric acid complex and the Raman spectrum measured.

#### Immobilization of the Amplification Components in a Polymer Matrix

[0044] In order to use the amplification components for analyte sensing *in vivo*, the components for the reactions must be immobilized in a polymer matrix that can be implanted subdermally. The matrix should be permeable to the analyte of interest and be stable within the body. Still further, the matrix should be prepared from biocompatible materials, or alternatively, coated with a biocompatible polymer. As used herein, the term "biocompatible" refers to a property of materials or matrix which produce no detectable adverse conditions upon implantation into an animal. While some inflammation may occur upon initial introduction of the implantable amplification system into a subject, the inflammation will not persist and the implant will not be rendered inoperable by encapsulation (*e.g.*, scar tissue).

[0045] The biocompatible matrix can include either a liquid substrate (*e.g.*, a coated dialysis tube) or a solid substrate (*e.g.*, polyurethanes/polyureas, silicon-containing polymers, hydrogels, solgels and the like). Additionally, the matrix can include a biocompatible shell prepared from, for example, dialysis fibers, teflon cloth, resorbable polymers or islet encapsulation materials. The matrix can be in the form of a disk, cylinder, patch, microspheres or a refillable sack and, as noted, can further incorporate a biocompatible mesh that allows for full tissue ingrowth with vascularization. While subdermal implantation is preferred, one skilled in the art would realize other implementation methods could be used. The key property of the matrix is its permeability to analytes and other reactants necessary for chemical amplification of a signal. For example, a glucose monitoring matrix must be permeable to glucose.

[0046] Finally, the implant should be optically transparent to the light from the optical source used for interrogating the IAS.

[0047] Figure 11 provides an illustration of several embodiments. As seen in FIGURE 11A, an amplification system can encompass a substrate layer, a transducer layer containing the amplification components, and a layer which is permeable to the analyte of interest.

[0048] The substrate layer be prepared from a polymer such as a polyurethane, silicone, silicon-containing polymer, chronoflex, P-HEMA or sol-gel. The substrate layer can be permeable to the analyte of interest, or it can be impermeable. For those embodiments in which the substrate layer is impermeable, the amplification components will be coated on the exterior of the substrate layer and further coated with a permeable layer (see FIGURE 11A).

[0049] In some embodiments, the amplification components will be entrapped or encased via covalent attachment, within a matrix which is itself permeable to the analyte of interest and biocompatible (see FIGURE 11B). In these embodiments, a second, permeable layer is unnecessary. Nevertheless, the use of a permeable layer such as a hydrogel which further facilitates tissue implantation is preferred (see FIGURE 11C).

#### 1. Biocompatible Matrix Materials

[0050] For those embodiments in which a polymer matrix is to be placed in contact with a tissue or fluid, the polymer matrix will preferably be a biocompatible matrix. In addition to being biocompatible, another requirement for this outermost layer of an implantable amplification system is that it be permeable to the analyte of interest. A number of biocompatible polymers are known, including some recently described silicon-containing polymers (see Copending Application Ser. No. 08/721,262, filed September 26, 1996, granted as US Patent No. 5,777,060) and hydrogels (see Copending Application Ser. No. 08/749,754, filed October 24, 1996, now granted as US Patent No. 5,786,439 and the corresponding EP-A-0876604). Silicone-containing polyurethane can be used for the immobilization of most of the glucose binding systems or other analyte amplification components. Other polymers such as silicone rubbers (NuSil 4550), biostable polyurethane (Biomer, Tecothane, Tecoflex, Pellethane and others), PEEK (polyether ether ketone) acrylics or combinations are also suitable.

a. Silicon-Containing Polymers

**[0051]** In one group of embodiments, the amplification components are either entrapped in, or covalently attached to, a silicone-containing polymer. This polymer is a homogeneous matrix prepared from biologically acceptable polymers whose hydrophobic/hydrophilic balance can be varied over a wide range to control the rate of polyhydroxylated analyte diffusion to the amplification components. The matrix can be prepared by conventional methods by the polymerization of diisocyanates, hydrophilic diols or diamines, silicone polymers and optionally, chain extenders. The resulting polymers are soluble in solvents such as acetone or ethanol and may be formed as a matrix from solution by dip, spray or spin coating. Preparation of biocompatible matrices for glucose monitoring have been described in co-pending applications Ser. No. 08/721,262 (granted as US Patent No. 5,777,060) and Ser. No. 08/749,754 (granted as US Patent No. 5,786,439).

**[0052]** The diisocyanates which are useful for the construction of a biocompatible matrix are those which are typically those which are used in the preparation of biocompatible polyurethanes. Such diisocyanates are described in detail in Szycher, SEMINAR ON ADVANCES IN MEDICAL GRADE POLYURETHANES, Technomic Publishing, (1995) and include both aromatic and aliphatic diisocyanates. Examples of suitable aromatic diisocyanates include toluene diisocyanate, 4,4'-diphenylmethane diisocyanate, 3,3'-dimethyl-4,4'-biphenyl diisocyanate, naphthalene diisocyanate and parapenylene diisocyanate. Suitable aliphatic diisocyanates include, for example, 1,6-hexamethylene diisocyanate (HDI), trimethylhexamethylene diisocyanate (TMDI), *trans*-1,4-cyclohexane diisocyanate (CHDI), 1,4-cyclohexane bis(methylene isocyanate) (BDI), 1,3-cyclohexane bis(methylene isocyanate) (H<sub>6</sub>XDI), isophorone diisocyanate (IPDI) and 4,4'-methylenebis(cyclohexyl isocyanate) (H<sub>12</sub>MDI). In preferred embodiments, the diisocyanate is isophorone diisocyanate, 1,6-hexamethylene diisocyanate, or 4,4'-methylenebis(cyclohexyl isocyanate). A number of these diisocyanates are available from commercial sources such as Aldrich Chemical Company (Milwaukee, Wisconsin, USA) or can be readily prepared by standard synthetic methods using literature procedures.

**[0053]** The quantity of diisocyanate used in the reaction mixture for the present compositions is typically about 50 mol% relative to the combination of the remaining reactants. More particularly, the quantity of diisocyanate employed in the preparation of the present compositions will be sufficient to provide at least about 100% of the —NCO groups necessary to react with the hydroxyl or amino groups of the remaining reactants. For example, a polymer which is prepared using *x* moles of diisocyanate, will use *a* moles of a hydrophilic polymer (diol, diamine or combination), *b* moles of a silicone polymer having functionalized termini, and *c* moles of a chain extender, such that  $x = a + b + c$ , with the understanding that *c* can be zero.

**[0054]** A second reactant used in the preparation of the biocompatible matrix described herein is a hydrophilic polymer. The hydrophilic polymer can be a hydrophilic diol, a hydrophilic diamine or a combination thereof. The hydrophilic diol can be a poly(alkylene)glycol, a polyester-based polyol, or a polycarbonate polyol. As used herein, the term "poly(alkylene)glycol" refers to polymers of lower alkylene glycols such as poly(ethylene)glycol, poly(propylene)glycol and polytetramethylene ether glycol (PTMEG). The term "polycarbonate polyol" refers to those polymers having hydroxyl functionality at the chain termini and ether and carbonate functionality within the polymer chain. The alkyl portion of the polymer will typically be composed of C2 to C4 aliphatic radicals, or in some embodiments, longer chain aliphatic radicals, cycloaliphatic radicals or aromatic radicals. The term "hydrophilic diamines" refers to any of the above hydrophilic diols in which the terminal hydroxyl groups have been replaced by reactive amine groups or in which the terminal hydroxyl groups have been derivatized to produce an extended chain having terminal amine groups. For example, a preferred hydrophilic diamine is a "diamino poly(oxyalkylene)" which is poly(alkylene)glycol in which the terminal hydroxyl groups are replaced with amino groups. The term "diamino poly(oxyalkylene)" also refers to poly(alkylene)glycols which have aminoalkyl ether groups at the chain termini. One example of a suitable diamino poly(oxyalkylene) is poly(propylene glycol)bis(2-aminopropyl ether). A number of the above polymers can be obtained from Aldrich Chemical Company. Alternatively, literature methods can be employed for their synthesis.

**[0055]** The amount of hydrophilic polymer which is used in the present compositions will typically be about 10% to about 80% by mole relative to the diisocyanate which is used. Preferably, the amount is from about 20% to about 60% by mole relative to the diisocyanate. When lower amounts of hydrophilic polymer are used, it is preferable to include a chain extender (see below).

**[0056]** Silicone polymers which are useful for the determination of polyhydroxylated analytes (*e.g.*, glucose) are typically linear. For polymers useful in glucose monitoring, excellent oxygen permeability and low glucose permeability is preferred. A particularly useful silicone polymer is a polydimethylsiloxane having two reactive functional groups (*i.e.*, a functionality of 2). The functional groups can be, for example, hydroxyl groups, amino groups or carboxylic acid groups, but are preferably hydroxyl or amino groups. In some embodiments, combinations of silicone polymers can be used in which a first portion comprises hydroxyl groups and a second portion comprises amino groups. Preferably, the functional groups are positioned at the chain termini of the silicone polymer. A number of suitable silicone polymers are commercially available from such sources as Dow Chemical Company (Midland, Michigan, USA) and General Electric Company (Silicones Division, Schenectady, New York, USA). Still others can be prepared by general synthetic

methods known to those skilled in the art, beginning with commercially available siloxanes (United Chemical Technologies, Bristol, Pennsylvania, USA). For use in the present invention, the silicone polymers will preferably be those having a molecular weight of from about 400 to about 10,000, more preferably those having a molecular weight of from about 2000 to about 4000. The amount of silicone polymer which is incorporated into the reaction mixture will depend on the desired characteristics of the resulting polymer from which the biocompatible membrane are formed. For those compositions in which a lower analyte penetration is desired, a larger amount of silicone polymer can be employed. Alternatively, for compositions in which a higher analyte penetration is desired, smaller amounts of silicone polymer can be employed. Typically, for a glucose sensor, the amount of siloxane polymer will be from 10% to 90% by mole relative to the diisocyanate. Preferably, the amount is from about 20% to 60% by mole relative to the diisocyanate.

**[0057]** In one group of embodiments, the reaction mixture for the preparation of biocompatible membranes will also contain a chain extender which is an aliphatic or aromatic diol, an aliphatic or aromatic diamine, alkanolamine, or combinations thereof. Examples of suitable aliphatic chain extenders include ethylene glycol, propylene glycol, 1,4-butanediol, 1,6-hexanediol, ethanolamine, ethylene diamine, butane diamine, 1,4-cyclohexanedimethanol. Aromatic chain extenders include, for example, *para*-di(2-hydroxyethoxy)benzene, *meta*-di(2-hydroxyethoxy)benzene, Ethacure 100® (a mixture of two isomers of 2,4-diamino-3,5-diethyltoluene), Ethacure 300® (2,4-diamino-3,5-di(methylthio)toluene), 3,3'-dichloro-4,4'-diaminodiphenylmethane, Polacure® 740 M (trimethylene glycol bis(*para*-aminobenzoate)ester), and methylenedianiline. Incorporation of one or more of the above chain extenders typically provides the resulting biocompatible membrane with additional physical strength, but does not substantially increase the glucose permeability of the polymer. Preferably, a chain extender is used when lower (*i.e.*, 10-40 mol %) amounts of hydrophilic polymers are used. In particularly preferred compositions, the chain extender is diethylene glycol which is present in from about 40% to 60% by mole relative to the diisocyanate.

#### b. Hydrogels

**[0058]** In some embodiments, the polymer matrix containing the amplification components can be further coated with a permeable layer such as a hydrogel, cellulose acetate, P-HEMA, nafion, or glutaraldehyde. A number of hydrogels are useful in the present invention. Hydrogels can be used as the polymer matrix which encase or entrap the amplification components. In still other embodiments, the amplification components can be covalently attached to a hydrogel.

**[0059]** Suitable hydrogels can be prepared from the reaction of a diisocyanate and a hydrophilic polymer, and optionally, a chain extender. The hydrogels are extremely hydrophilic and will have a water pickup of from about 120% to about 400% by weight, more preferably from about 150% to about 400%. The diisocyanates, hydrophilic polymers and chain extenders which are used in this aspect of the invention are those which are described above. The quantity of diisocyanate used in the reaction mixture for the present compositions is typically about 50 mol% relative to the combination of the remaining reactants. More particularly, the quantity of diisocyanate employed in the preparation of the present compositions will be sufficient to provide at least about 100% of the —NCO groups necessary to react with the hydroxyl or amino groups of the remaining reactants. For example, a polymer which is prepared using  $x$  moles of diisocyanate, will use  $a$  moles of a hydrophilic polymer (diol, diamine or combination), and  $b$  moles of a chain extender, such that  $x = a + b$ , with the understanding that  $b$  can be zero. Preferably, the hydrophilic diamine is a "diamino poly(oxyalkylene)" which is poly(alkylene)glycol in which the terminal hydroxyl groups are replaced with amino groups. The term "diamino poly(oxyalkylene)" also refers to poly(alkylene)glycols which have aminoalkyl ether groups at the chain termini. One example of a suitable diamino poly(oxyalkylene) is poly(propylene glycol) bis(2-aminopropyl ether). A number of diamino poly(oxyalkylenes) are available having different average molecular weights and are sold as Jeffamines® (for example, Jeffamine 230, Jeffamine 600, Jeffamine 900 and Jeffamine 2000). These polymers can be obtained from Aldrich Chemical Company. Alternatively, literature methods can be employed for their synthesis.

**[0060]** The amount of hydrophilic polymer which is used in the present compositions will typically be about 10% to about 100% by mole relative to the diisocyanate which is used. Preferably, the amount is from about 50% to about 90% by mole relative to the diisocyanate. When amounts less than 100% of hydrophilic polymer are used, the remaining percentage (to bring the total to 100%) will be a chain extender.

**[0061]** Polymerization of the substrate layer components or the hydrogel components can be carried out by bulk polymerization or solution polymerization. Use of a catalyst is preferred, though not required. Suitable catalysts include dibutyltin bis(2-ethylhexanoate), dibutyltin diacetate, triethylamine and combinations thereof. Preferably dibutyltin bis(2-ethylhexanoate) is used as the catalyst. Bulk polymerization is typically carried out at an initial temperature of about 25°C (ambient temperature) to about 50°C, in order to insure adequate mixing of the reactants. Upon mixing of the reactants, an exotherm is typically observed, with the temperature rising to about 90-124°C. After the initial exotherm, the reaction flask can be heated at from 75°C to 125°C, with 90°C to 100°C being a preferred temperature range. Heating is usually carried out for one to two hours.

**[0062]** Solution polymerization can be carried out in a similar manner. Solvents which are suitable for solution po-

lymerization include, tetrahydrofuran, dimethylformamide, dimethyl sulfoxide, dimethylacetamide, halogenated solvents such as 1,2,3-trichloropropane, and ketones such as 4-methyl-2-pentanone. Preferably, THF is used as the solvent. When polymerization is carried out in a solvent, heating of the reaction mixture is typically carried out for at least three to four hours, and preferably at least 10-20 hours. At the end of this time period, the solution polymer is typically cooled to room temperature and poured into DI water. The precipitated polymer is collected, dried, washed with hot DI water to remove solvent and unreacted monomers, then redried.

## 2. Methods for Immobilizing the Amplification Components

**[0063]** Immobilization of the amplification components into a polymer matrix described above can be accomplished by incorporating the components into the polymerization mixture during formation of the matrix. If the components are prepared having suitable available functional groups the components will become covalently attached to the polymer during formation. Alternatively, the components can be entrapped within the matrix during formation.

### a. Covalent attachment

**[0064]** In one group of embodiments, the substrates of the fluorescence generating reaction are immobilized in, or on the surface of, an appropriate base material using covalent bonding chemistry. The substrates can be covalently bonded to the base material using any of a variety of covalent bonding techniques commonly used for polymer synthesis, for example, via condensation, condensation-elimination or free radical polymerizations. For compounds of formula I, the appropriate functionalization could be accomplished at one or more of the pendant groups  $R^1$ ,  $R^3$  or  $R^4$ . For condensation type polymerizations, the use of a single covalent linker would lead to a terminal attachment, whereas the use of two or three R groups leads to chain extension and crosslinking, respectively. For free radical type polymerizations, chain extension can occur with a single functionalized R group.

**[0065]** As outlined in Example 3, an amine-terminated block copolymer, poly(propylene glycol)-*block*-poly(ethylene glycol)-*block*-poly(propylene glycol)bis(2-aminopropyl ether), can be reacted with a diisocyanate to form a biocompatible hydrophilic polyurea. Incorporation of a hydroxy functionalized fluorescent monomer provides a polymer containing a covalently attached amplification component, in this example, as a chain terminating urethane linkage. In any case, the goal of immobilization is to incorporate the amplification components into a matrix in such a way as to retain the molecular system's desired optical and chemical activity. FIGURE 13 shows the reversible change in fluorescence for a solution of anthracene-boronate as a function of glucose concentration over the physiological range.

**[0066]** In some embodiments, the amplification components will not be substituted with suitable functional groups for covalent attachment to a polymer during formation. In this instance, the reagents are simply entrapped. The amount of amplification component used for either the covalent or entrapped methods will typically be on the order of about 0.5% to about 10% by weight, relative to the total weight of the biocompatible matrix. One of skill in the art will understand that the amounts can be further adjusted upward or downward depending on the intensity of the signal produced as well as the sensitivity of the detector.

## Optical Systems

**[0067]** The second aspect of the biosensors described herein consists of an optical system for interrogating the IAS and detecting the signal thus produced by the IAS. As used herein, the term "interrogating" refers to illumination of the amplification components in the IAS and subsequent detection of the emitted light. One embodiment illustrating a transdermal optical system is shown in FIGURE 1, where the light source (S) shines through the skin, and a detector (D) detects the fluorescence transmitted through the skin. FIGURES 3-6 show embodiments where there is no transmission through the skin, as the light source is implanted or the light travels via a fiber optic to the amplification system positioned at the end of the fiber.

**[0068]** FIGURE 1 shows a schematic of the subdermally implanted optical glucose monitoring system. The light source (S) could be a lamp, an LED, or a laser diode (pulsed or modulated). The detector (D) can be a photodiode, CCD detector or photomultiplier tube. Optionally, filters are used to filter the incident and/or emitted beams of light to obtain desired wavelengths. The source and detector are shown in FIGURE 1 as positioned outside the body, although the source and/or the detector can be implanted as shown in FIGURES 3-6. The biocompatible material (e.g., silicone, polyurethane or other polymer) with the immobilized amplification components is implanted under the skin. The light source is used to illuminate the implanted system, and the detector detects the intensity of the emitted (typically fluorescent) light. Other modes of interaction may also be used, such as absorbance, transmittance, or reflectance, when the change in the amount of light or spectral character of the light that is measured by the detector or spectrometer is modulated by the local analyte (e.g., glucose) concentration. In yet other detection methods, the fluorescence lifetimes are measured rather than the light intensity.

[0069] In the case of fluorescence, the ratio of intensity of excitation and emission can be used to quantify the glucose signal. In a preferred embodiment, the ratio of fluorescence from the amplification components to the fluorescence of a calibration fluorophore is measured. This method eliminates errors due to registration and variations of light transport through the skin (*e.g.*, caused by different skin tones).

#### Methods for the Detection and Quantitation of Analytes *In Vivo*

[0070] In view of the above compositions and devices, the present invention also provides methods for the detection and quantitation of an analyte *in vivo*. More particularly, the methods involve quantifying the amount of a polyhydroxylated analyte in an individual, by

(a) interrogating a subcutaneously implanted amplification system with an energy source to provide an excited amplification system which produces an energy emission corresponding to the amount of the polyhydroxylated analyte; and

(b) detecting the emission to thereby quantify the amount of the polyhydroxylated analyte in the individual.

[0071] The amplification and optical systems are essentially those which have been described above, and the preferred embodiments including components of the biocompatible matrix (*e.g.*, silicon-containing polymers, hydrogels, *etc.*) are also those which have been described above. Prior to carrying out the present method, the amplification system is implanted in an individual using minimally invasive surgical or microsurgical techniques. The purpose of such implantation is to place in contact the amplification system and the analyte of interest (*e.g.*, in fluid or tissue containing the analyte). Accordingly, the amplification system can be placed in or under the skin, or alternatively within an organ or blood vessel. When transdermal interrogation is used, the amplification system is preferably placed subcutaneously about 1-2 mm below the skin surface. For fiber optic mediated interrogation, the depth will be from 1-4 mm below the skin surface. For those embodiments in which the optical system and amplification components are in communication with an insulin pump, the placement can be at even greater depths.

[0072] The polyhydroxylated analyte can be any of a variety of endogenous or xenobiotic substances which have two or more hydroxy functional groups in positions vicinal to each other. Preferably, the analyte is a sugar, more preferably glucose.

[0073] As already noted, suitable amplification systems have been described above. However, in certain preferred embodiments, the implanted amplification system will further comprise a calibration fluorophore which provides a signal not interfering with the signal from the amplification components. In some preferred embodiments, the IAS comprises a boronate based sugar binding compound, more preferably those of formula I and a calibration fluorophore. Suitable calibration fluorophores are those fluorescent dyes such as fluoresceins, coumarins, oxazines, xanthenes, cyanines, metal complexes and polyaromatic hydrocarbons which produce a fluorescent signal. In other preferred embodiments, the amplification system will comprise a calibration fluorophore and a compound of formula I in which D<sup>1</sup> is a long wavelength fluorescent dye.

[0074] In order that those skilled in the art can more fully understand this invention, the following examples illustrating the general principles for preparation of glucose responsive systems are set forth. These examples are given solely for purposes of illustration, and should not be considered as expressing limitations unless so set forth in the appended claims. All parts are percentages by weight, unless otherwise stated.

#### EXAMPLES

[0075] In the examples below, Example 1 provides the synthesis of various chemical amplification components. Example 2 provides the synthesis of biocompatible polymers. Example 3 provides a description of the covalent attachment of certain amplification components to a biocompatible polymer.

#### General Materials and Methods

[0076] Unless otherwise noted, the materials used in the examples were obtained from Aldrich Chemical Co., Milwaukee, Wisconsin, USA or Sigma Chemical Company, St. Louis, Missouri, USA.

#### EXAMPLE 1

##### *1.1 Synthesis of fluorescein labeled boronic acid (FABA)*

[0077] Preparation of a fluorescein labeled boronic acid (FABA) was carried out as described in Uziel, *et al.*, *Biochem.*

*Biophys. Res. Commun.*, **180**:1233 (1991).

[0078] Briefly, a solution (5 mL) of 3-aminophenylboronic acid was prepared in DI water. The pH was adjusted to 8 with NaOH and NaHCO<sub>3</sub>. Fluorescein isothiocyanate (0.45 mmol) was added and the mixture was stirred overnight at room temperature. The fluorescein-labeled boronate was isolated as yellow crystals. At pH 10, the fluorescence of the compound was significantly decreased by the addition of glucose to the solution.

## 1.2 Synthesis of labeled boronic acids

[0079] The labeled boronic acids described herein are prepared as outlined in the scheme depicted in FIGURES 9 and 10.

[0080] 2,4,6-(*o*-(bromomethyl)phenyl)boroxin (1) was prepared according to a literature procedure from 2,4,6-*o*-Tolyl-boroxin substituting benzoylperoxide (BPO) for the AIBN catalyst (see, Hawkins, *et al.*, *J. Am. Chem. Soc.* **82**:3863 (1960)).

[0081] 9-((N-Methyl-N-(*o*-boronobenzyl)amino)methyl)anthracene (2) was synthesized by a modification of a literature procedure (A)(see, James, *et al.*, *J. Am. Chem. Soc.* **117**:8982 (1995)) or by method (B).

[0082] (A): 2,4,6-(*o*-(bromomethyl)phenyl)boroxin (100 mg, 0.18 mmol) and 9-((methylamino)methyl)anthracene (254 mg, 1.1 mmol) were refluxed in 50 mL chloroform for 3 h. The mixture was cooled to 0°C in an ice bath and filtered through a sintered glass frit. Solvent was removed from the filtrate under reduced pressure. The crude material was washed with 3 x 3 mL portions of acetonitrile/water (9/1, v/v) to remove the hydrochloride salt of 9-((methylamino)methyl)anthracene to provide 2 as a pale yellow powder: 155 mg (48%); mp 149-151°C (lit. mp 147-152°C); <sup>1</sup>H NMR (300.13 MHz, CD<sub>3</sub>OD) δ 2.27 (s, 3H), 3.85 (s, 2H), 4.60 (s, 2H), 7.00-7.80 (m, 8H), 8.05 (m, 2H), 8.30-8.70 (m, 3H).

[0083] (B): A solution of 9-((methylamino)methyl)anthracene (1.00 g, 4.5 mmol), 2-bromobenzyl bromide (1.13 g, 4.5 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.691 g, 5.0 mmol) in 50 mL of acetonitrile was refluxed under nitrogen for 18 hr. The solution was filtered on a sintered-glass filter and solvent was removed from the filtrate under reduced pressure to yield 9-(N-Methyl-N-(*o*-bromobenzyl)amino)methyl)anthracene (95 % by NMR). The resulting solid was taken up in diethyl ether (50 mL), and treated at 0°C with 1 equiv of butyllithium. The mixture was stirred at 0°C for 2 h at which time 5 equiv of trimethylborate was added via a cannula. After warming the mixture to room temperature, 50 mL of water was added to quench the reaction. The ether layer was separated, washed with 3 x 10 mL water, and dried over sodium sulfate. Removal of the solvent under reduced pressure provided a solid identical to that obtained in (A) in 52 % yield.

## 2,2-Dimethylpropane-1,3-diyl(*o*-(bromomethyl)phenyl)boronate (3)

[0084] 2,4,6-(*o*-(bromomethyl)phenyl)boroxin (5.0 g, 25.4 mmol) and 2,2-dimethyl-1,3-propanediol (8.73 g, 83.8 mmol) were refluxed in toluene (200 mL) with azeotropic removal of water (Dean-Stark) for 2,4 h. The solvent was removed under vacuum to give a solid/oil mixture which was then slurried in 25 mL toluene and silica gel. The resulting mixture was filtered on a sintered-glass frit and rinsed thoroughly with cold toluene until the washings revealed no evidence of product by TLC. The combined filtrate was evaporated under reduced pressure to give 3 as a pale yellow oil: 6.76 g (94%); <sup>1</sup>H NMR (300.13 MHz, CD<sub>3</sub>CN) δ 1.05 (s, 6H), 3.81 (s, 4H), 4.95 (s, 2H), 7.15-7.45 (m, 3H), 7.74 (m, 1H).

## 9,10-Bis((Methylamino)methyl)anthracene (4)

[0085] The title compound was prepared according to a literature procedure (see, James, *et al.*, *J. Am. Chem. Soc.* **117**:8982 (1995)).

## 9-((5-hydroxypentyl)aminomethyl)anthracene (5)

[0086] A solution of anthraldehyde (9.595 g, 0.0465 mol) and 5-amino-1-pentanol (15.00 g, 0.116 mol) dissolved in 500 mL ethanol at 0°C was stirred for 3 h. After warming to room temperature the solvent was removed under reduced pressure, and 150 mL of ethanol containing NaBH<sub>4</sub> (4.65 g, 0.1229 mol) was added slowly with stirring. The resulting mixture was allowed to stir overnight. The ethanol was removed under reduced pressure and to the brown oil/solid mixture was added 150 mL diethyl ether. Water was added dropwise to this solution until the evolution of hydrogen ceased, followed by the addition of 500 mL water. The ether phase was isolated, washed with 2 x 50 mL water, dried over sodium sulfate and filtered on a sintered-glass frit. Removal of the solvent afforded 12.17 g (89.2 % yield) of 5 as a golden solid; <sup>1</sup>H NMR (300.13 MHz, CD<sub>3</sub>CN) δ 1.51 (m, 6H), 2.81 (t, 2H), 3.49 (t, 2H), 4.68 (s, 2H), 7.52 (m, 4H), 8.05 (d, 2H), 8.44 (m, 3H); <sup>13</sup>C-{<sup>1</sup>H} NMR (75.4 MHz, CDCl<sub>3</sub>) δ 133.1, 132.0, 131.7, 130.4, 128.6, 127.4, 126.2, 125.1, 62.9, 51.1, 45.8, 33.5, 30.3, 24.8.

**9-((N-(5-hydroxypentyl)-N-(ethylamino)methyl)anthracene (6)**

[0087] 9-((5-hydroxypentyl)aminomethyl)anthracene (1.00 g, 3.41 mmol) and  $K_2CO_3$  (0.518 g, 3.75 mmol) were taken up in 25 mL acetonitrile. Ethyl bromide (11.14 g, 102 mmol) was added and the mixture was refluxed under nitrogen for 24 h. The mixture was filtered on a sintered-glass frit and the solvent and excess ethyl bromide was removed under reduced pressure. Removal of the solvent afforded 1.07 g (98% yield) of **6** as a yellow solid;  $^1H$  NMR (300.13 MHz,  $CD_3CN$ )  $\delta$  1.15 (m, 2H), 1.38 (m, 5H), 1.81 (m, 2H), 3.05 (m, 4H), 3.49 (t, 2H), 5.21 (s, 2H), 7.45 (m, 2H), 7.62 (m, 2H), 8.05 (d, 2H), 8.44 (m, 3H);  $^{13}C$ - $\{^1H\}$  NMR (75.4 MHz,  $CDCl_3$ )  $\delta$  131.8, 131.3, 130.8, 129.6, 128.0, 125.6, 124.0, 61.7, 53.1, 49.4, 48.7, 31.4, 23.9, 23.3, 10.0.

**9-((N-(5-hydroxypentyl)-N-(o-boronobenzyl)amino)methyl)anthracene (7)**

[0088] 9-((5-hydroxypentyl)aminomethyl)anthracene (1.06 g, 3.51 mmol) and  $K_2CO_3$  (0.56 g, 4.05 mmol) were taken up in 15 mL acetonitrile. A solution of 2,2-dimethylpropane-1,3-diyl(o-(bromomethyl)phenyl)boronate (1.02 g, 3.51 mmol) in 5 mL acetonitrile was added and the mixture was refluxed under nitrogen for 24 h. The mixture was filtered on a sintered-glass frit and the solvent was removed under reduced pressure. The resulting solid was triturated with acetonitrile/water (4:1, v/v) to deprotect the boronate group, filtered on a sintered-glass frit and vacuum dried to yield **9** as a pale yellow solid (0.744 g, 48% yield);  $^1H$  NMR (300.13 MHz,  $CD_3OD$ )  $\delta$  0.95 (m, 2H), 1.15 (m, 2H), 1.60 (m, 2H), 2.82 (m, 2H), 3.45 (m, 2H), 4.45 (s, 2H), 5.08 (s, 2H), 7.1-7.8 (m, 8H), 8.07 (d, 2H), 8.21 (d, 2H), 8.62 (s, 1H);  $^{13}C$ - $\{^1H\}$  NMR (75.4 MHz,  $CDCl_3$ )  $\delta$  135.8, 133.0, 131.5, 129.1, 128.6, 127.8, 126.5, 124.9, 62.4, 61.9, 53.7, 49.7, 32.6, 24.9, 24.6.

[0089] 10-(hydroxymethyl)-9-anthraldehyde (**8**) was prepared according to a literature procedure (see, Lin, *et al.*, *J. Org. Chem.* **44**:4701 (1979)).

**10-(hydroxymethyl)-9-((methylimino)methyl)anthracene (9)**

[0090] 10-(hydroxymethyl)-9-anthraldehyde (3.00 g, 12.7 mmol) was added to 50 mL of a saturated solution of methylamine in methanol and stirred at room temperature for 2 h. The solvent and excess methylamine was removed under reduced pressure to afford the imine as a bright yellow powder (quant);  $^1H$  NMR (300.13 MHz,  $DMSO-d_6$ )  $\delta$  3.35 (s, 3H), 5.51 (s, 2H), 7.61 (m, 4H), 8.55 (m, 4H), 9.48 (s, 1 H).

**10-(hydroxymethyl)-9-((methylamino)methyl)anthracene (10)**

[0091] 10-(hydroxymethyl)-9-((methylimino)methyl)anthracene (1.00 g, 4.0 mmol) was slurried in 25 mL isopropanol.  $NaBH_4$  (0.454 g, 12.0 mmol) was added as a solid and the solution was stirred at room temperature for 72 h. The mixture was filtered on a sintered-glass frit and the solvent was removed under reduced pressure to yield **10** as a bright yellow powder (0.853 g, 86% yield);  $^1H$  NMR (300.13 MHz,  $CD_3OD$ )  $\delta$  2.55 (s, 3H), 4.64 (s, 2H), 5.56 (s, 2H), 7.55 (m, 4H), 8.38 (m, 2H); 8.50 (m, 2H);  $^{13}C$ - $\{^1H\}$  NMR (75.4 MHz,  $CD_3OD$ )  $\delta$  133.4, 133.0, 131.6, 131.5, 126.9, 126.7, 126.2, 125.7, 57.2, 47.9, 36.5.

**10-(hydroxymethyl)-9-N-(o-boronobenzyl)amino)methylanthracene (11)**

[0092] 10-(hydroxymethyl)-9-((methylamino)methyl)anthracene (0.800 g, 3.18 mmol) and  $K_2CO_3$  (0.56 g, 4.05 mmol) were taken up in 15 mL acetonitrile. A solution of 2,2-dimethylpropane-1,3-diyl(o-(bromomethyl)phenyl)boronate **3** (1.00 g, 3.44 mmol) in 5 mL acetonitrile was added and the mixture was refluxed under nitrogen for 24 h. The mixture was filtered hot on a sintered-glass frit and upon cooling, a yellow solid precipitated. The resulting solid was triturated with acetonitrile/water (4:1, v/v), filtered on a sintered-glass frit and vacuum dried to yield **11** as a bright yellow solid (0.632 g, 51.6 % yield);  $^1H$  NMR (300.13 MHz,  $CD_3OD$ )  $\delta$  2.58 (s, 3H), 4.58 (s, 2H), 5.22 (s, 2H), 5.61 (s, 2H), 7.62 (m, 6H), 7.80 (m, 2H), 8.18 (m, 2H), 8.58 (m, 2H);  $^{13}C$ - $\{^1H\}$  NMR (75.4 MHz,  $CD_3OD$ )  $\delta$  136.9, 136.2, 135.9, 132.9, 132.7, 131.4, 129.9, 128.3, 127.1, 126.8, 126.5, 124.9, 124.1, 63.8, 57.1, 50.9, 40.7.

**EXAMPLE 2**

[0093] This example provides the preparation of polymers used for the immobilization of the amplification components.

## 2.1 Biocompatible polymers (Silicone-Containing polymers and Hydrogel Coatings)

### 2.1a Silicone-Containing Polymers

#### Synthesis of a Biocompatible Silicone/Polyurethane Patch Material for Subdermal Implantation

**[0094]** To an oven-dried, 100 mL, 3-neck round bottom flask fitted with a mechanical stirrer, condenser, and under nitrogen was added 65 mL of anhydrous THF, 80 mg of dibutyltin dilaurate (catalytic), 5.05 grams of poly(propylene glycol-b-ethylene glycol-b-propylene glycol) bis(2-aminopropyl ether) (8.4 mmol, .75 equiv.), 7.01 grams polydimethylsiloxane, aminopropyl dimethyl-terminated (average MW 2500) (2.8 mmol, .25 equiv.), and 2.94 grams of 4,4'-methylenebis(cyclohexylisocyanate) (11.2 mmol, 1 equiv.) dried over 4 Å molecular sieves. An initial exotherm raised the temperature from 26 to 39°C. The reaction solution was heated at reflux for about 15 hours, the heat was removed, and the solution was allowed to cool to room temperature. The cooled solution, now visibly more viscous, was poured into approximately 900 mL of rapidly stirring DI water. The precipitated polymer was collected and washed again in approximately 800 mL DI water. The collected polymer was dried *in vacuo* at 80°C.

**[0095]** A bulk polymerization method of polymer formation was carried out with isophorone diisocyanate, PEG 600, diethylene glycol and aminopropyl terminated polydimethyl siloxane as follows.

**[0096]** Isophorone diisocyanate (4.44 g, 20 mmol, 100 mol%) was dried over molecular sieves and transferred to a 100 mL round bottom flask fitted with a nitrogen purge line and a reflux condenser. PEG 600 (2.40 g, 4.0 mmol, 20 mol%), diethylene glycol (1.06 g, 10 mmol, 50 mol%) and aminopropyl terminated polydimethylsiloxane (15 g, 6.0 mmol, 30 mol%, based on a 2500 average molecular weight) were added to the flask. Heating was initiated using a heating mantle until a temperature of 50°C was obtained. Dibutyltin bis(2-ethylhexanoate) (15 mg) was added and the temperature increased to about 95°C. The solution was continuously stirred at a temperature of 65°C for a period of 4 hr during which time the mixture became increasingly viscous.. The resulting polymer was dissolved in 50 mL of hot THF and cooled. After cooling, the solution was poured into 5 L of stirring DI water. The precipitated polymer was torn into small pieces and dried at 50°C until a constant weight was achieved.

**[0097]** A solution polymerization method using 1,6-hexamethylene diisocyanate, PEG 200 and aminopropyl terminated polydimethylsiloxane was carried out as follows.

**[0098]** Dried 1,6-hexamethylene diisocyanate (1.34 g, 8 mmol, 100 mol%) was added to a 100 mL 3-neck flask containing 20 mL of dry THF. PEG 200 (0.8 g, 4.0 mmol, 50 mol%) was added with stirring followed by addition of aminopropyl terminated polydimethylsiloxane (10 g, 4.0 mmol, 50 mol%). The resulting solution was warmed to 50°C and dibutyltin bis(2-ethylhexanoate) (about 15 mg) was added. After an initial temperature rise to 83°C, the mixture was warmed and held at 70°C for 12 hr, during which time the mixture had become very viscous. After cooling, the mixture was poured into 3 L of rapidly stirring DI water. The precipitated polymer was collected, washed with DI water (3X), torn into small pieces and dried at 50°C until a constant weight was obtained.

**[0099]** Table 1 provides five formulations for representative polymers are suitable in biocompatible matrices. The polymers were prepared by solution polymerization.

TABLE 1

Representative Polymer Formulations				
Polymer	Diisocyanate	Poly(alkylene glycol)	Aliphatic diol	Siloxane
1	1,6-Hexamethylene	PEG 600 (20%)	DEG (60%)	Aminopropyl (20%)
2	Isophorone	PEG 600 (20%)	DEG (50%)	Aminopropyl (30%)
3	1,6-Hexamethylene	PEG 600 (50%)	None	Aminopropyl (50%)
4	1,6-Hexamethylene	PEG 400 (40%)	None	Aminopropyl (60%)
5	1,6-Hexamethylene	PEG 600 (60%)	None	Aminopropyl (40%)

### 2.1b Hydrogel Coatings and Polymers

**[0100]** Hydrogels suitable for use as biosensor coatings were prepared by combining a diisocyanate with an equivalent molar amount of a hydrophilic diol or diamine or with a combination of diol or diamine and chain extender such that the molar amount of the combination was equivalent to the diisocyanate. The polymerizations were carried out in a one-pot reaction using THF as solvent and a trace catalyst (tributyltin ethylhexanoate). The reactions were heated

to reflux and held at this temperature overnight (about 16 hours). The resulting polymer solution was poured into a large volume of DI water at about 20°C and then filtered, dried, and washed with boiling DI water. The resulting polymer was again dried then taken up in 2-propanol (as a 5 wt% solution) and used for encasing an amplification component.

**[0101]** Formulations of representative hydrogel coatings and polymers are provided in Table 2.

TABLE 2

Representative Polymer Formulations			
Polymer	Diisocyanate	Hydrophilic diol or diamine	Chain Extender
1	1,6-Hexamethylene	Jeffamine 600 (95%)	Butanediol (5%)
2	1,6-Hexamethylene	Jeffamine 2000 (100%)	None
3	1,6-Hexamethylene	Jeffamine 2000 (90%)	Butanediol (10%)
4	1,6-Hexamethylene	PEG 2000 (90%)	Butanediol (10%)
5	1,6-Hexamethylene	Jeffamine 230 (30 %)	Ethylene diamine (70%)
6	1,6-Hexamethylene	PEG 600 (75%)	Ethylene diamine (25%)
7	Isophorone	PEG 600 (75%)	Butanediol (25%)
8	Isophorone	Jeffamine 900 (70%)	1,6-Diaminohexane (25%)
9	Isophorone	Jeffamine 900 (50%)	1,2-Diaminocyclo-hexane (50%)
10	Isophorone	Jeffamine 900 (50%)	Isophorone diamine (50%)

## 2.2 Incorporation of Amplification Components into a Biocompatible Matrix

### 2.2a Incorporation of FABA (fluorescein labeled boronic acid) into a membrane.

**[0102]** The fluorescence of FABA is pH sensitive. In order to measure the fluorescence quenching due to the addition of glucose, a method was developed to incorporate the FABA in a polymeric membrane at pH 10. A 7% by weight solution of a hydrophilic polyurethane was made in 2-propanol. This base. solution was combined with a 0.2 mmol solution of FABA dissolved in pH 10.0 phosphate buffer (0.1M). The final concentration of the membrane was approximately 5% by weight. A membrane was cast by spreading 3 ml of the solution onto a glass plate and allowing the membrane to dry. A portion of the membrane was then attached to a thin piece of glass and placed in the diagonal of a fluorescence cuvette. Fluorescence spectra were run in pH 7.4 buffer solution. FIGURE 12 shows the calibration curve generated from this experiment. As seen, the fluorescence intensity is quenched by the glucose at pH 7.4.

### EXAMPLE 3

**[0103]** This example provides the description of covalent attachment of certain components to biocompatible polymers.

#### Incorporation of (6) into a hydrophilic polymer via a urethane linkage

**[0104]** To a three-necked 200 mL flask equipped with a condenser and a teflon stir bar was added 60 mL of dry THF, poly(propylene glycol)-*block*-poly(ethylene glycol)-*block*-poly(propylene glycol)bis(2-aminopropyl ether) (ave. Mn ca. 900, Jeffamine 900®) (6.30 g, 7.0 mmol), and dibutyltin bis(2-ethylhexanoate) catalyst (0.052 g). While stirring, 2.49 g (9.5 mmol) of 4,4'-methylenebis(cyclohexylisocyanate) was added and the resulting mixture was allowed to stir at room temperature overnight. 9-((5-hydroxypentyl)aminomethyl)anthracene (0.32 g, 1.0 mmol) was added and the mixture was refluxed for 2 h. The flask was removed from the heat, and the stir bar was replaced with a mechanical stirrer. 1,6-hexamethylenediamine (0.29 g, 2.5 mmol) in 2 mL THF was added to the solution with stirring and then refluxed for 1.5 h. The viscous mass was added to 500. mL water to produce an amber colored solid which was air dried on a Buchner funnel and placed in a vacuum oven overnight. Films of the polymer were prepared by casting ethanol solutions (1 g polymer/10 mL ethanol) on glass plates and air drying.

**Incorporation of (7) into a hydrophilic polymer via a urethane linkage**

[0105] To a three-necked 200 mL flask equipped with a condenser and a teflon stir bar was added 60 mL of dry THF, poly(propylene glycol)-*block*-poly(ethylene glycol)-*block*-poly(propylene glycol)bis(2-aminopropyl ether) (ave. Mn ca. 900, Jeffamine 900®) (6.30 g, 7.0 mmol), and dibutyltin bis(2-ethylhexanoate) catalyst (0.052 g). While stirring, 2.49 g (9.5 mmol) of 4,4'-methylenebis(cyclohexylisocyanate) was added and the resulting mixture was allowed to stir at room temperature overnight. 9-((5-hydroxypentyl)-N-(o-boronobenzyl)amino)methyl)anthracene (0.44 g, 1.0 mmol) was added and the mixture was refluxed for 2 h. The flask was removed from the heat, and the stir bar was replaced with a mechanical stirrer. 1,6-hexamethylenediamine (0.29 g, 2.5 mmol) in 2 mL THF was added to the solution with stirring and then refluxed for 1.5 h. The viscous mass was added to 500 mL water to produce an amber colored solid which was air dried on a Buchner funnel and placed in a vacuum oven overnight. Films of the polymer were prepared by casting ethanol solutions (1 g polymer/10 mL ethanol) on glass plates and air drying.

**Incorporation of (11) into a hydrophilic polymer via a urethane linkage**

[0106] To a three-necked 200 mL flask equipped with a condenser and a teflon stir bar was added 60 mL of dry THF, poly(propylene glycol)-*block*-poly(ethylene glycol)-*block*-poly(propylene glycol)bis(2-aminopropyl ether) (ave. Mn ca. 900, Jeffamine 900®) (0.63 g, 0.7 mmol), and dibutyltin bis(2-ethylhexanoate) catalyst (0.0052 g). While stirring, 0.249 g (0.95 mmol) of 4,4'-methylenebis(cyclohexylisocyanate) was added and the resulting mixture was allowed to stir at room temperature overnight. 10-(hydroxymethyl)-9-N-(o-boronobenzyl)amino)methyl)anthracene (0.04 g, 0.1 mmol) was added and the mixture was refluxed for 2 h. The flask was removed from the heat, and the stir bar was replaced with a mechanical stirrer. 1,6-hexamethylenediamine (0.029 g, 0.25 mmol) in 2 mL THF was added to the solution with stirring and then refluxed for 1.5 h. The viscous mass was added to 500 mL water to produce an amber colored solid which was air dried on a Buchner funnel and placed in a vacuum oven overnight. Films of the polymer were prepared by casting ethanol solutions (1 g polymer/10 mL ethanol) on glass plates and air drying.

**Claims**

1. An implantable amplification system comprising a biocompatible polymer matrix and amplification components which produce a polyhydroxylated analyte signal upon interrogation by an optical system, wherein said amplification components comprise an arylboronic acid moiety attached to an amine-functionalized dye molecule, and wherein said amplification components do not require resonance energy transfer for production of said signal.
2. An implantable amplification system in accordance with claim 1, wherein said dye molecule is selected from the group consisting of anthracene and fluorescein.
3. An implantable amplification system in accordance with claim 1 or 2, wherein said arylboronic acid moiety attached to an amine-functionalised dye molecule is entrapped within said biocompatible matrix.
4. An implantable amplification system in accordance with claim 1, 2 or 3 wherein said biocompatible polymer matrix comprises a polymer prepared from a reaction mixture of:
  - (a) a diisocyanate, said diisocyanate comprising about 50 mol % of the reactants in said mixture;
  - (b) a hydrophilic polymer which is a member selected from the group consisting of a hydrophilic polymer diol, a hydrophilic polymer diamine and combinations thereof;
  - (c) a siloxane polymer having amino, hydroxyl or carboxylic acid functional groups at the chain termini.
5. An implantable amplification system in accordance with claim 4, wherein said biocompatible matrix further comprises an outer hydrogel coating, wherein said hydrogel is formed from a reaction mixture of:
  - (a) a diisocyanate, said diisocyanate comprising about 50 mol % of the reacting in said mixture;
  - (b) a hydrophilic polymer which is a member selected from the group consisting of a hydrophilic polymer diol, a hydrophilic polymer diamine and combinations thereof; and optionally;
  - (c) a chain extender,

.said hydrogel having a water pickup of from about 120% to about 400% by weight.

6. A method for quantifying the amount of a polyhydroxylated analyte in an individual, said method comprising:

- (a) interrogating a subcutaneously implanted amplification system of any one of claims 1 to 5 with an energy source to provide an excited amplification system which produces an energy emission corresponding to said amount of said polyhydroxylated analyte; and
- (b) detecting said emission to thereby quantify the amount of said polyhydroxylated analyte in said individual.

7. A method in accordance with claim 6, wherein said energy source is a laser diode.

8. A method in accordance with claim 6 or 7, wherein said polyhydroxylated analyte is glucose.

9. A biosensor for measuring the amount of a polyhydroxylated analyte *in vivo*, said sensor comprising:

- (a) an implantable amplification system of any one of claims 1 to 5; and
- (b) an optical system comprising an optical source and a detector which detects said signal thereby measuring the *in vivo* amount of said analyte.

10. A biosensor in accordance with claim 9, wherein said optical source is a LED.

11. A biosensor in accordance with claim 9, wherein said optical system further comprises at least one filter and wherein said optical source is a LED.

## Patentansprüche

1. Ein implantierbares Verstärkungssystem, das eine biologisch verträgliche Polymermatrix und Verstärkungskomponenten umfasst, die beim Abfragen durch ein optisches System ein Signal eines polyhydroxylierten Analyten erzeugen, wobei die Verstärkungskomponenten einen Arylboronsäurerest umfassen, der an ein Amin-funktionalisiertes Farbstoffmolekül gebunden ist, und wobei die Verstärkungskomponenten zur Erzeugung des Signals keinen Resonanzenergietransfer erfordern.

2. Implantierbares Verstärkungssystem nach Anspruch 1, bei dem das Farbstoffmolekül aus der Gruppe bestehend aus Anthracen und Fluorescein ausgewählt ist.

3. Implantierbares Verstärkungssystem nach Anspruch 1 oder 2, bei dem der Arylboronsäurerest, der an ein Amin-funktionalisiertes Farbstoffmolekül gebunden ist, innerhalb der biologisch verträglichen Matrix eingeschlossen ist.

4. Implantierbares Verstärkungssystem nach Anspruch 1, 2 oder 3, bei dem die biologisch verträgliche Polymermatrix ein Polymer umfasst, das aus einem Reaktionsgemisch aus

- (a) einem Diisocyanat, wobei das Diisocyanat etwa 50 mol-% der Reaktanten in dem Gemisch umfasst,
- (b) einem hydrophilen Polymer, das eine Verbindung ist, die aus der Gruppe bestehend aus einem hydrophilen Diolpolymer, einem hydrophilen Diaminpolymer und Kombinationen davon ausgewählt ist, und
- (c) einem Siloxanpolymer, das an den Kettenenden funktionelle Amino-, Hydroxyloder Carbonsäuregruppen aufweist, hergestellt wird.

5. Implantierbares Verstärkungssystem nach Anspruch 4, bei dem die biologisch verträgliche Polymermatrix ferner eine äußere Hydrogelbeschichtung umfasst, wobei das Hydrogel aus einem Reaktionsgemisch aus

- (a) einem Diisocyanat, wobei das Diisocyanat etwa 50 mol-% der Reaktanten in dem Gemisch umfasst,
- (b) einem hydrophilen Polymer, das eine Verbindung ist, die aus der Gruppe bestehend aus einem hydrophilen Diolpolymer, einem hydrophilen Diaminpolymer und Kombinationen davon ausgewählt ist, und gegebenenfalls
- (c) einem Kettenverlängerungsmittel,

gebildet wird, wobei das Hydrogel eine Wasseraufnahme von etwa 120 Gew.-% bis etwa 400 Gew.-% aufweist.

6. Ein Verfahren zur Quantifizierung der Menge eines polyhydroxylierten Analyten in einem Lebewesen, wobei das Verfahren umfasst:

- (a) Abfragen eines subkutan implantierten Verstärkungssystems nach einem der Ansprüche 1 bis 5 mit einer Energiequelle zur Bereitstellung eines angeregten Verstärkungssystems, das eine Energieemission erzeugt, die der Menge des polyhydroxylierten Analyten entspricht, und  
(b) Erfassen der Emission, so dass dadurch die Menge des polyhydroxylierten Analyten in dem Lebewesen quantifiziert wird.

7. Verfahren nach Anspruch 6, bei dem die Energiequelle eine Laserdiode ist.

8. Verfahren nach Anspruch 6 oder 7, bei dem der polyhydroxylierte Analyt Glukose ist.

9. Ein Biosensor zur Messung der Menge eines polyhydroxylierten Analyten in vivo, wobei der Sensor

- (a) ein implantierbares Verstärkungssystem nach einem der Ansprüche 1 bis 5 und  
(b) ein optisches System umfasst, das eine optische Quelle und einen Detektor umfasst, der das Signal erfasst, wodurch die in-vivo-Menge des Analyten gemessen wird.

10. Biosensor nach Anspruch 9, bei dem die optische Quelle eine LED ist.

11. Biosensor nach Anspruch 9, bei dem das optische System ferner mindestens einen Filter umfasst und die optische Quelle eine LED ist.

## Revendications

1. Système d'amplification implantable comprenant une matrice de polymère biocompatible et des composants d'amplification qui produisent un signal d'analyte polyhydroxylé lors d'une interrogation par un système optique, dans lequel lesdits composants d'amplification comprennent un fragment acide arylboronique attaché à une molécule anhydre fonctionnalisée par une amine, et dans lequel lesdits composants d'amplification ne nécessitent pas de transfert d'énergie de résonance pour la production dudit signal.

2. Système d'amplification implantable selon la revendication 1, dans lequel ladite molécule anhydre est choisie dans le groupe constitué de l'anthracène et de la fluorescéine.

3. Système d'amplification implantable selon la revendication 1 ou 2, dans lequel ledit fragment acide arylboronique attaché à une molécule anhydre fonctionnalisée par une amine est emprisonné dans ladite matrice biocompatible.

4. Système d'amplification implantable selon la revendication 1, 2 ou 3, dans lequel ladite matrice de polymère biocompatible comprend un polymère préparé à partir d'un mélange réactionnel de :

- (a) un diisocyanate, ledit diisocyanate comprenant environ 50 % en mole des réactifs dans ledit mélange ;  
(b) un polymère hydrophile qui est un élément choisi dans le groupe constitué d'un polymère diol hydrophile, d'un polymère diamine hydrophile et de combinaisons de ceux-ci ;  
(c) un polymère siloxane ayant des groupes fonctionnels amino, hydroxyles ou acide carboxyliques à l'extrémité de la chaîne.

5. Système d'amplification implantable selon la revendication 4, dans lequel ladite matrice de polymère biocompatible comprend en outre un revêtement externe d'hydrogel, dans lequel ledit hydrogel est formé à partir d'un mélange réactionnel de :

- (a) un diisocyanate, ledit diisocyanate comprenant environ 50 % en mole des réactifs dans ledit mélange ;  
(b) un polymère hydrophile qui est un élément choisi dans le groupe constitué d'un polymère diol hydrophile, d'un polymère diamine hydrophile et de combinaisons de ceux-ci ; et éventuellement  
(c) un extenseur de chaîne,

ledit hydrogel ayant une fixation d'eau comprise dans la plage allant d'environ 120 % à environ 400 % en poids.

6. Procédé de quantification de la quantité d'un analyte polyhydroxylé dans un individu, ledit composé comprenant

les étapes consistant à :

- 5 (a) interroger un système d'amplification implanté par voie sous-cutanée selon l'une quelconque des revendications 1 à 5 avec une source d'énergie pour fournir un système d'amplification excité qui produit une émission d'énergie correspondant à ladite quantité dudit analyte polyhydroxylé ; et  
(b) détecter ladite émission pour quantifier la quantité dudit analyte polyhydroxylé dans ledit individu.

7. Procédé selon la revendication 6, dans lequel ladite source d'énergie est une diode laser.


10 8. Procédé selon la revendication 6 ou 7, dans lequel ledit analyte polyhydroxylé est le glucose.

9. Biocapteur pour mesurer la quantité d'un analyte polyhydroxylé in vivo, ledit capteur comprenant :

- 15 (a) un système d'amplification implantable selon l'une quelconque des revendications 1 à 5 ; et  
(b) un système optique comprenant une source optique et un détecteur qui détecte ledit signal mesurant ainsi la quantité in vivo dudit analyte.

10. Biocapteur selon la revendication 9, dans lequel ladite source optique est une diode électroluminescente (LED : light emitting diode).

20 11. Biocapteur selon la revendication 9, dans lequel ledit système optique comprend en outre au moins un filtre et dans lequel ladite source optique est une diode électroluminescente.



*FIG. 1.*




FIG. 2.




FIG. 3.




FIG. 4.




FIG. 5.




FIG. 6.





FIG. 7





ANTHRACENE

FLUORESCIN - 1

FLUORESCIN - 2

FLUORESCIN - 3



COUNARIN 153

NILE BLUE  
(OXAZINE)

FIG. 8




FIG. 9




FIG. 12




FIG. 10.




FIG. 14A.




FIG. 14B.




FIG. 11




FIG. 13